Biotech Stock MorphoSys Catapults 56% As Novartis Agrees To Buy It For $2.9 Billion

Biotech Stock MorphoSys Catapults 56% As Novartis Agrees To Buy It For $2.9 Billion

Biotech Stock MorphoSys Catapults 56% As Novartis Agrees To Buy It For $2.9 Billion · Investor's Business Daily

ALLISON GATLIN

February 5, 2024 1 min read

Novartis agreed late Monday to buy MorphoSys for about $2.9 billion. The cancer-focused biotech stock catapulted to a nearly three-year high.

Continue Reading

Terms and Privacy Policy

Privacy Dashboard